Literature DB >> 16797678

Claudin 1 differentiates endometrioid and serous papillary endometrial adenocarcinoma.

Gábor Sobel1, Júlia Németh, András Kiss, Gabor Lotz, István Szabó, Nóra Udvarhelyi, Zsuzsa Schaff, Csilla Páska.   

Abstract

OBJECTIVE: The expression of claudins, the main tight junction proteins involved in cell adhesion and carcinogenesis, was studied in endometrioid (type I) and seropapillary (type II) endometrial adenocarcinoma. The characteristics and possible diagnostic potential of claudin expression pattern were investigated in the two cancer types having different prognosis.
METHODS: Protein and mRNA expression of claudins was evaluated in 17 endometrioid carcinomas and 15 seropapillary adenocarcinomas by immunohistochemistry and real-time PCR in comparison with 38 cases of hyperplasia, normal proliferative and secretory endometrium samples. Further, protein expressions used in diagnostics (estrogen and progesterone receptors, p53, PCNA and beta-catenin) were also studied.
RESULTS: In endometrioid carcinoma and hyperplasia low claudin 1 and high claudin 2 protein contents, whereas in seropapillary adenocarcinoma high claudin 1 and low claudin 2 levels were detected. Intense protein expression was noted for claudins 3, 4, 5, and 7, without significantly different patterns in carcinoma, hyperplasia, secretory, and proliferative endometrium. Real-time PCR results confirmed differences in claudin 1 but not claudin 2 mRNA expression, whereas some minor discrepancies were observed in comparison with immunohistochemistry patterns.
CONCLUSION: The two types of endometrial adenocarcinomas were well distinguished by claudins 1 and 2 by immunohistochemistry, claudins 3, 4, and 7, however, did not prove useful in distinguishing the two entities. The similar claudin pattern seen in hyperplasia and endometrioid carcinoma and the differences regarding seropapillary adenocarcinoma support the dualistic model of endometrial carcinogenesis. The claudin pattern of the two tumor types might reflect a different cellular or pathogenetic pathway as well as a different cell adhesion behavior explaining the invasive properties.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16797678     DOI: 10.1016/j.ygyno.2006.04.005

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  26 in total

1.  Expression of claudins and their prognostic significance in noninvasive urothelial neoplasms of the human urinary bladder.

Authors:  Eszter Székely; Péter Törzsök; Péter Riesz; Anna Korompay; Attila Fintha; Tamás Székely; Gábor Lotz; Péter Nyirády; Imre Romics; József Tímár; Zsuzsa Schaff; András Kiss
Journal:  J Histochem Cytochem       Date:  2011-08-10       Impact factor: 2.479

2.  Expression and clinical significance of FAK and Src proteins in human endometrial adenocarcinoma.

Authors:  Nikolaos A Chatzizacharias; Constantinos Giaginis; Elisavet Gatzidou; Gerasimos Tsourouflis; Ioannis Sfiniadakis; Paraskevi Alexandrou; Stamatios E Theocharis
Journal:  Pathol Oncol Res       Date:  2010-11-07       Impact factor: 3.201

3.  Selected immuno-histochemical markers in curettage specimens and their correlation with final pathologic findings in endometrial cancer patients.

Authors:  Basil R Obeidat; Ismail I Matalka; Alia A Mohtaseb; Nabih S Al-Kaisi
Journal:  Pathol Oncol Res       Date:  2012-10-10       Impact factor: 3.201

4.  Claudin-1 as a Biomarker of Cervical Cytology and Histology.

Authors:  Márta Benczik; Ádám Galamb; Róbert Koiss; Attila Kovács; Balázs Járay; Tamás Székely; Tímea Szekerczés; Zsuzsa Schaff; Gábor Sobel; Csaba Jeney
Journal:  Pathol Oncol Res       Date:  2016-01       Impact factor: 3.201

5.  Insights into endometrial serous carcinogenesis and progression.

Authors:  Oluwole Fadare; Wenxin Zheng
Journal:  Int J Clin Exp Pathol       Date:  2009-01-10

6.  Claudin-1, -2, -3, -4, -7, -8, and -10 protein expression in biliary tract cancers.

Authors:  Zsuzsanna Németh; Attila Marcell Szász; Péter Tátrai; Júlia Németh; Hajnalka Gyorffy; Aron Somorácz; Attila Szíjártó; Péter Kupcsulik; András Kiss; Zsuzsa Schaff
Journal:  J Histochem Cytochem       Date:  2008-10-14       Impact factor: 2.479

Review 7.  Claudins in cancer: bench to bedside.

Authors:  Makoto Osanai; Akira Takasawa; Masaki Murata; Norimasa Sawada
Journal:  Pflugers Arch       Date:  2016-09-13       Impact factor: 3.657

8.  Endometrial cancer: what is new in adjuvant and molecularly targeted therapy?

Authors:  Flora Zagouri; George Bozas; Eftichia Kafantari; Marinos Tsiatas; Nikitas Nikitas; Meletios-A Dimopoulos; Christos A Papadimitriou
Journal:  Obstet Gynecol Int       Date:  2010-02-02

9.  The genomics and genetics of endometrial cancer.

Authors:  Andrea J O'Hara; Daphne W Bell
Journal:  Adv Genomics Genet       Date:  2012-03

10.  Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis.

Authors:  Mandi M Murph; Wenbin Liu; Shuangxing Yu; Yiling Lu; Hassan Hall; Bryan T Hennessy; John Lahad; Marci Schaner; Aslaug Helland; Gunnar Kristensen; Anne-Lise Børresen-Dale; Gordon B Mills
Journal:  PLoS One       Date:  2009-05-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.